# Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

> **NCT05308901** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Providence Health & Services** · enrollment: 6 (actual)

## Conditions studied

- Melanoma, Uveal

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT05308901
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-02
- **Primary completion:** 2024-12-03
- **Final completion:** 2027-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05308901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05308901, "Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05308901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*